Alembic Pharmaceuticals liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5.40×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.75×	1.75×	1.69×	2.12×	1.78×
0.78×	0.78×	0.75×	0.99×	0.88×
196	196	83.5	120	75.5
1,949	1,949	1,675	1,624	1,273

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

APLLTD₹794.85

Alembic Pharmaceuticals Ltd.

· Pharma & Health

₹ CrorePeersAJANTPHARM IPCALAB TORNTPHARM ALIVUS AKUMS AGARWALEYE ADVENZYMES AARTIPHARMMcap ₹15,623 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	5.40
Current Ratio	1.78	2.12	1.69	1.75	1.75
Quick Ratio	0.88	0.99	0.75	0.78	0.78
Cash, Equiv & ST Investments	75.5	120.2	83.5	196.4	196.4
Working Capital	1,273.1	1,623.6	1,675.5	1,948.8	1,948.8

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.